This article is a correction to:
CRISPR nuclease off-target activity and mitigation strategies
Beeke Wienert1
M. Kyle Cromer2,3,4*- 1Graphite Bio, Inc., South San Francisco, CA, United States
- 2Department of Surgery, University of California, San Francisco, San Francisco, CA, United States
- 3Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States
- 4Eli and Edythe Broad Center for Regeneration Medicine, University of California, San Francisco, San Francisco, CA, United States
A Corrigendum on
CRISPR nuclease off-target activity and mitigation strategies
by Wienert B and Cromer MK (2022). Front. Genome Ed. 4:1050507. doi: 10.3389/fgeed.2022.1050507
In the published article, “Dobbs et al., 2022” was cited incorrectly in the article. The citation has now been inserted at the correct location in the section, “Methods to find off-targets sites in genome editing applications”, paragraph three, and should read: “These methods vary widely in their approach and even starting material, using cell-free genomic DNA in vitro (Kim et al., 2015; Cameron et al., 2017; Tsai et al., 2017; Kim and Kim, 2018; Lazzarotto et al., 2020), in intact live cells ex vivo (Crosetto et al., 2013; Tsai et al., 2015; Yan et al., 2017; Wienert et al., 2019; 2020; Zhu et al., 2019; Dobbs et al., 2022), and in vivo animal models (Akcakaya et al., 2018; Wienert et al., 2019; Liang et al., 2022).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: gene therapy, off-target activity, in vivo delivery, genome editing, CRISPR/Cas9, next-generating sequencing
Citation: Wienert B and Cromer MK (2023) Corrigendum: CRISPR nuclease off-target activity and mitigation strategies. Front. Genome Ed. 4:1112956. doi: 10.3389/fgeed.2022.1112956
Received: 30 November 2022; Accepted: 02 December 2022;
Published: 20 January 2023.
Edited and reviewed by:
Ayal Hendel, Bar-Ilan University, IsraelCopyright © 2023 Wienert and Cromer. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: M. Kyle Cromer, a3lsZS5jcm9tZXJAdWNzZi5lZHU=